Exact Sciences Corporation EXAS is well-poised to grow in the coming quarters, courtesy of the ongoing momentum in its Cologuard and Oncotype DX tests. The company continues to invest in its pipeline ...

Is Exact Sciences (NASDAQ: EXAS) about to go on a sustained run? The medical diagnostics specialist has lagged the market over the trailing-12-month period, but the stock is rebounding. In the past ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Exact Sciences (EXAS) one of those stocks right now? By taking a look at the ...

Exact SciencesEXAS stock surged Tuesday on a broad third-quarter beat that "should allay fears of a market slowdown," an analyst said. The company is well known for Cologuard, a stool-based test that ...

Due to their high-entropy nature, I’m not the biggest fan of specialized healthcare enterprises. With Exact Sciences (NASDAQ: EXAS) straddling the edge of biotech and medtech, EXAS stock represents a ...

Exact Sciences (EXAS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% ...

Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The US equity ...

Exact Sciences' claim to fame is Cologuard, an at-home stool-based test it developed for the early detection of colorectal cancer (CRC) in patients with average risk. CRC is the third-most-common ...